Klyx

KLYX Bio is a Cambridge-based biotechnology company focused on developing next-generation small molecule therapeutics to treat metabolic and age-related diseases. The company's primary research centers on modulating mitochondrial function and cellular energy homeostasis to address the root causes of chronic conditions. Founded by prominent longevity researcher Dr. David Sinclair and a team of experts in metabolism, KLYX Bio utilizes a proprietary discovery platform to identify compounds that enhance mitochondrial efficiency. Their current pipeline is in the preclinical stage, with a focus on indications such as non-alcoholic steatohepatitis (NASH) and other metabolic disorders. The company aims to translate breakthrough insights in aging biology into transformative medicines that improve human healthspan.